People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
PDUFA date of March 27, 2025 for CARDAMYST (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) - Commercial capabilities build out in process, with proposed launch in PSVT targe ...
PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)- Commercial capabilities ...
The UK-based consumer healthcare company will be modernizing its facility along Brook Road, where it conducts R&D for such ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Boing Boing on MSN4d
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with itOn Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.
Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback